User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Reward pathways in Parkinson's disease: clinical and theoretical implications.

Primary tabs

Torta, Diana [UCL] Castelli, Lorys

The mesolimbic and mesocortical circuits are particularly involved in reward-related behavior in humans. Because these systems may be in some way altered in Parkinson's disease (PD), it is likely that some psychiatric manifestations of PD, such as hedonistic homeostatic dysregulation and pathological gambling, as well as impulsive decision making, may be ascribed to their involvement. The aim of the current article was to review recent literature on this topic in order to analyze whether these disturbances share a common ground and whether actual theoretical frameworks on addiction prove a useful tool for their interpretation.

Document type Article de périodique (Journal article) – Synthèse de littérature
Publication date 2008
Language Anglais
Journal information "Psychiatry and Clinical Neurosciences" - Vol. 62, no.2, p. 203-213 (2008)
Peer reviewed yes
Publisher Wiley-Blackwell Publishing Asia (Richmond)
issn 1323-1316
e-issn 1440-1819
Publication status Publié
Affiliation University of Turin - Department of Psychology
MESH Subject Aged ; Humans ; Limbic System ; Male ; Middle Aged ; Motivation ; Nerve Net ; Parkinson Disease ; Reward ; Risk Factors ; Substance-Related Disorders ; Antiparkinson Agents ; Cerebral Cortex ; Decision Making ; Disruptive, Impulse Control, and Conduct Disorders ; Dopamine ; Female ; Gambling ; Homeostasis
Links
  1. Agid Y, Adv. Neurol., 91, 365 (2003)
  2. Ferreri F., Agbokou C., Gauthier S., Recognition and management of neuropsychiatric complications in Parkinson's disease, 10.1503/cmaj.060542
  3. Aarsland D, J. Neurol. Neurosurg. Psychiatry, 67, 492 (1999)
  4. Allain H., Depression in Parkinson's disease, 10.1136/bmj.320.7245.1287
  5. Mössner R, Henneberg A, Schmitt A, Syagailo Y V, Grässle M, Hennig T, Simantov R, Gerlach M, Riederer P, Lesch K P, Allelic variation of serotonin transporter expression is associated with depression in Parkinson’s disease, 10.1038/sj.mp.4000849
  6. Wermuth L., Bech P., Depression in Parkinson's disease ? a review, 10.1111/j.1600-0404.2006.00718.x
  7. Castelli L., Perozzo P., Zibetti M., Crivelli B., Morabito U., Lanotte M., Cossa F., Bergamasco B., Lopiano L., Chronic Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson’s Disease: Effects on Cognition, Mood, Anxiety and Personality Traits, 10.1159/000093213
  8. Dujardin Kathy, Sockeel Pascal, Devos David, Delliaux Marie, Krystkowiak Pierre, Destée Alain, Defebvre Luc, Characteristics of apathy in Parkinson's disease, 10.1002/mds.21316
  9. Richard IH, Adv. Neurol., 96, 42 (2005)
  10. Isella V, Physical anhedonia in Parkinson's disease, 10.1136/jnnp.74.9.1308
  11. German Dwight C., Manaye Kebreten, Smith Wade K., Woodward Donald J., Saper Clifford B., Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization, 10.1002/ana.410260403
  12. Kish Stephen J., Shannak Kathleen, Hornykiewicz Oleh, Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease, 10.1056/nejm198804073181402
  13. Agid Y, Adv. Neurol., 60, 148 (1993)
  14. Leentjens Albert F.G., Van den Akker Marjan, Metsemakers Job F.M., Lousberg Richel, Verhey Frans R.J., Higher incidence of depression preceding the onset of Parkinson's disease: A register study, 10.1002/mds.10387
  15. Ishihara L., Brayne C., A systematic review of depression and mental illness preceding Parkinson's disease, 10.1111/j.1600-0404.2006.00579.x
  16. Martin-Soelch C, Leenders K.L, Chevalley A.-F, Missimer J, Künig G, Magyar S, Mino A, Schultz W, Reward mechanisms in the brain and their role in dependence: evidence from neurophysiological and neuroimaging studies, 10.1016/s0165-0173(01)00089-3
  17. Goerendt I. K., Reward Processing in Health and Parkinson's Disease: Neural Organization and Reorganization, 10.1093/cercor/bhg105
  18. Nader Karim, Bechara Antoine, van der Kooy Derek, NEUROBIOLOGICAL CONSTRAINTS ON BEHAVIORAL MODELS OF MOTIVATION, 10.1146/annurev.psych.48.1.85
  19. Thobois S, Dominey P, Decety J, Pollak P, Gregoire M C., Broussolle E, Overactivation of primary motor cortex is asymmetrical in hemiparkinsonian patients : , 10.1097/00001756-200003200-00026
  20. Kunig G, Neuroreport, 11, 3681 (2000)
  21. Nakamura K., Role of Dopamine in the Primate Caudate Nucleus in Reward Modulation of Saccades, 10.1523/jneurosci.4853-05.2006
  22. Mattox Samuel T., Valle-Inclán Fernando, Hackley Steven A., Psychophysiological evidence for impaired reward anticipation in Parkinson’s disease, 10.1016/j.clinph.2006.05.026
  23. van Boxtel Geert J.M., Böcker Koen B.E., Cortical Measures of Anticipation, 10.1027/0269-8803.18.23.61
  24. Lawrence Andrew D, Evans Andrew H, Lees Andrew J, Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?, 10.1016/s1474-4422(03)00529-5
  25. Quinn N, Br. J. Psychiatry, 142, 296 (1983)
  26. Vogel HP, Pharmacopsychiatria, 16, 107 (1983)
  27. Priebe S, Pharmacopsychiatria, 17, 109 (1984)
  28. Nausieda Paul A., Sinemet “Abusers” : , 10.1097/00002826-198512000-00002
  29. Tack E., Cuypere G., Jannes C., Remouchamps A., Levodopa addiction. : A case study, 10.1111/j.1600-0447.1988.tb06347.x
  30. Uitti Ryan J., Tanner C. M., Rajput A. H., Goetz C. G., Klawans H. L., Thiessen B., Hypersexuality with Antiparkinsonian Therapy : , 10.1097/00002826-198910000-00002
  31. SOYKA MICHAEL, HUPPERT DOREEN, L-dopa abuse in a patient with former alcoholism, 10.1111/j.1360-0443.1992.tb01908.x
  32. Weinman E, Am. J. Geriatr. Psychiatry, 3, 81 (1995)
  33. Spigset O, Pharmacotherapy, 17, 1027 (1997)
  34. Courty Eve, Durif Franck, Zenut Marie, Courty Pascal, Lavarenne Jeanine, Psychiatric and Sexual Disorders Induced by Apomorphine in Parkinsonʼs Disease : , 10.1097/00002826-199704000-00005
  35. Merims Doron, Galili-Mosberg Ronit, Melamed Eldad, Is there addiction to levodopa in patients with Parkinson's disease?, 10.1002/1531-8257(200009)15:5<1014::aid-mds1041>3.0.co;2-o
  36. Giovannoni G, Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies, 10.1136/jnnp.68.4.423
  37. Gschwandtner Ute, Aston Jacqueline, Renaud Susanne, Fuhr Peter, Pathologic Gambling in Patients with Parkinson's Disease : , 10.1097/00002826-200105000-00009
  38. Serrano-Duenas M, German J. Psychiatry, 5, 62 (2002)
  39. Houeto J L, Behavioural disorders, Parkinson's disease and subthalamic stimulation, 10.1136/jnnp.72.6.701
  40. Müller U., Reuter M., Hermann W., Gertz H. J., Levodopa-Abhängigkeit bei Parkinsonkrankheit Fallbericht und Literaturübersicht : Fallbericht und Literaturübersicht, 10.1007/s00115-002-1329-9
  41. Bearn Jennifer, Evans Andrew, Kelleher Michael, Turner Kirsten, Lees Andrew, Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study☆☆Supplementary, 10.1016/j.drugalcdep.2004.06.005
  42. Romana Pezzella Francesca, Colosimo Carlo, Vanacore Nicola, Di Rezze Simone, Chianese Melania, Fabbrini Giovanni, Meco Giuseppe, Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease : Dopaminergic Addiction in PD, 10.1002/mds.20288
  43. Molina Jos� Antonio, S�inz-Artiga Mar�a Jos�, Fraile Alicia, Jim�nez-Jim�nez F�lix Javier, Villanueva Clara, Ort�-Pareja Miguel, Bermejo-P F�lix, Pathologic gambling in Parkinson's disease: A behavioral manifestation of pharmacologic treatment?, 10.1002/1531-8257(200009)15:5<869::aid-mds1016>3.0.co;2-i
  44. Seedat Soraya, Kesler Simon, Niehaus Dana J.H., Stein Dan J., Pathological gambling behaviour: Emergence secondary to treatment of Parkinson's disease with dopaminergic agents, 10.1002/1520-6394(2000)11:4<185::aid-da8>3.0.co;2-h
  45. Driver-Dunckley E., Samanta J., Stacy M., Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease:, 10.1212/01.wnl.0000076478.45005.ec
  46. Kurlan Roger, Disabling repetitive behaviors in Parkinson's disease, 10.1002/mds.10625
  47. Dodd M. Leann, Klos Kevin J., Bower James H., Geda Yonas E., Josephs Keith A., Ahlskog J. Eric, Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease, 10.1001/archneur.62.9.noc50009
  48. Imamura Akiko, Uitti Ryan J., Wszolek Zbigniew K., Dopamine agonist therapy for Parkinson disease and pathological gambling, 10.1016/j.parkreldis.2006.02.004
  49. Avanzi Maurizio, Baratti Mario, Cabrini Silvia, Uber Elena, Brighetti Gianni, Bonfà Flavio, Prevalence of pathological gambling in patients with Parkinson's disease, 10.1002/mds.21072
  50. Weintraub Daniel, Siderowf Andrew D., Potenza Marc N., Goveas Joseph, Morales Knashawn H., Duda John E., Moberg Paul J., Stern Matthew B., Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease, 10.1001/archneur.63.7.969
  51. Czernecki V, Motivation, reward, and Parkinson's disease: influence of dopatherapy, 10.1016/s0028-3932(02)00108-2
  52. Cools Roshan, Barker Roger A, Sahakian Barbara J, Robbins Trevor W, l-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease, 10.1016/s0028-3932(03)00117-9
  53. Perretta James G, Pari Giovanna, Beninger Richard J, Effects of Parkinson Disease on Two Putative Nondeclarative Learning Tasks : Probabilistic Classification and Gambling, 10.1097/01.wnn.0000187939.81541.1d
  54. Stocchi Fabrizio, Pathological gambling in Parkinson's disease, 10.1016/s1474-4422(05)70177-0
  55. Solomon Richard L., Corbit John D., An opponent-process theory of motivation: II. Cigarette addiction., 10.1037/h0034534
  56. Koob G. F., Drug Abuse: Hedonic Homeostatic Dysregulation, 10.1126/science.278.5335.52
  57. Koob G, Drug Addiction, Dysregulation of Reward, and Allostasis, 10.1016/s0893-133x(00)00195-0
  58. Torta Riccardo, Berra Carlotta, Binaschi Luca, Borio Roberto, Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies, 10.1007/s00520-006-0194-7
  59. Leenders K, Parkinsonism Relat. Disord., 5, 61 (1999)
  60. Goerendt IK, Parkinsonism Relat. Disord., 5, 58 (1999)
  61. Heidbreder Christian A., Gardner Eliot L., Xi Zheng-Xiong, Thanos Panayotis K., Mugnaini Manolo, Hagan Jim J., Ashby Charles R., The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence, 10.1016/j.brainresrev.2004.12.033
  62. LEFOLL B, GOLDBERG S, SOKOLOFF P, The dopamine D receptor and drug dependence: Effects on reward or beyond?, 10.1016/j.neuropharm.2005.04.022
  63. Wise R., Yokel R., DeWit H, Both positive reinforcement and conditioned aversion from amphetamine and from apomorphine in rats, 10.1126/science.1257748
  64. Ranaldi Robert, Beninger Richard J., The effects of systemic and intracerebral injections of D1 and D2 agonists on brain stimulation reward, 10.1016/0006-8993(94)90708-0
  65. Beninger R, Dopamine D1-like Receptors and Reward-related Incentive Learning, 10.1016/s0149-7634(97)00019-5
  66. Esposito Ennio, Serotonin-Dopamine Interaction as a Focus of Novel Antidepressant Drugs, 10.2174/138945006775515455
  67. American Psychiatry Association., Diagnostic and Statistical Manual of Mental Disorders (2000)
  68. Blume S. B, Pathological gambling, 10.1136/bmj.311.7004.522
  69. Holden C., ADDICTION: 'Behavioral' Addictions: Do They Exist?, 10.1126/science.294.5544.980
  70. Swann Alan C., What Is Bipolar Disorder?, 10.1176/appi.ajp.163.2.177
  71. Riley David E., Reversible Transvestic Fetishism in a Man With Parkinson's Disease Treated With Selegiline : , 10.1097/00002826-200207000-00008
  72. Voon V., Hassan K., Zurowski M., Duff-Canning S., de Souza M., Fox S., Lang A. E., Miyasaki J., Prospective prevalence of pathologic gambling and medication association in Parkinson disease, 10.1212/01.wnl.0000218206.20920.4d
  73. Gerlach M., Double K., Arzberger T., Leblhuber F., Tatschner T., Riederer P., Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum, 10.1007/s00702-003-0027-5
  74. Reuter Jan, Raedler Thomas, Rose Michael, Hand Iver, Gläscher Jan, Büchel Christian, Pathological gambling is linked to reduced activation of the mesolimbic reward system, 10.1038/nn1378
  75. Evenden J. L., Varieties of impulsivity, 10.1007/pl00005481
  76. McDonald Jennifer, Schleifer Laura, Richards Jerry B, de Wit Harriet, Effects of THC on Behavioral Measures of Impulsivity in Humans, 10.1038/sj.npp.1300176
  77. Winstanley Catharine A, Dalley Jeffrey W, Theobald David EH, Robbins Trevor W, Fractionating Impulsivity: Contrasting Effects of Central 5-HT Depletion on Different Measures of Impulsive Behavior, 10.1038/sj.npp.1300434
  78. Madden Gregory J., Petry Nancy M., Badger Gary J., Bickel Warren K., Impulsive and self-control choices in opioid-dependent patients and non-drug-using control patients: Drug and monetary rewards., 10.1037//1064-1297.5.3.256
  79. Madden Gregory J., Bickel Warren K., Jacobs Eric A., Discounting of delayed rewards in opioid-dependent outpatients: Exponential or hyperbolic discounting functions?, 10.1037//1064-1297.7.3.284
  80. Bickel Warren K., Amass Leslie, Crean John P., Badger Gary J., Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients, 10.1007/s002130051096
  81. Petry Nancy M., Delay discounting of money and alcohol in actively using alcoholics, currently abstinent alcoholics, and controls, 10.1007/s002130000638
  82. Coffey Scott F., Gudleski Gregory D., Saladin Michael E., Brady Kathleen T., Impulsivity and rapid discounting of delayed hypothetical rewards in cocaine-dependent individuals., 10.1037//1064-1297.11.1.18
  83. Rogers Robert D, Robbins Trevor W, Investigating the neurocognitive deficits associated with chronic drug misuse, 10.1016/s0959-4388(00)00204-x
  84. Bechara Antoine, Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective, 10.1038/nn1584
  85. Schoenbaum Geoffrey, Roesch Matthew R., Stalnaker Thomas A., Orbitofrontal cortex, decision-making and drug addiction, 10.1016/j.tins.2005.12.006
  86. Rogers R, Dissociable Deficits in the Decision-Making Cognition of Chronic Amphetamine Abusers, Opiate Abusers, Patients with Focal Damage to Prefrontal Cortex, and Tryptophan-Depleted Normal Volunteers Evidence for Monoaminergic Mechanisms, 10.1016/s0893-133x(98)00091-8
  87. Dias R., Robbins T. W., Roberts A. C., Dissociation in prefrontal cortex of affective and attentional shifts, 10.1038/380069a0
  88. Fellows L. K., Ventromedial frontal cortex mediates affective shifting in humans: evidence from a reversal learning paradigm, 10.1093/brain/awg180
  89. Izquierdo A., Bilateral Orbital Prefrontal Cortex Lesions in Rhesus Monkeys Disrupt Choices Guided by Both Reward Value and Reward Contingency, 10.1523/jneurosci.1921-04.2004
  90. Camille N., The Involvement of the Orbitofrontal Cortex in the Experience of Regret, 10.1126/science.1094550
  91. Bechara A, J. Neurosci., 19, 5473 (1999)
  92. Robbins Trevor W., Chemistry of the mind: Neurochemical modulation of prefrontal cortical function, 10.1002/cne.20717
  93. Clarke H. F., Cognitive Inflexibility After Prefrontal Serotonin Depletion, 10.1126/science.1094987
  94. Clarke H. F., Prefrontal Serotonin Depletion Affects Reversal Learning But Not Attentional Set Shifting, 10.1523/jneurosci.3690-04.2005
  95. Rogers Robert D, Tunbridge Elizabeth M, Bhagwagar Zubin, Drevets Wayne C, Sahakian Barbara J, Carter Cameron S, Tryptophan Depletion Alters the Decision-Making of Healthy Volunteers through Altered Processing of Reward Cues, 10.1038/sj.npp.1300001
  96. Evers Elizabeth A T, Cools Roshan, Clark Luke, van der Veen Frederik M, Jolles Jelle, Sahakian Barbara J, Robbins Trevor W, Serotonergic Modulation of Prefrontal Cortex during Negative Feedback in Probabilistic Reversal Learning, 10.1038/sj.npp.1300663
Bibliographic reference Torta, Diana ; Castelli, Lorys. Reward pathways in Parkinson's disease: clinical and theoretical implications.. In: Psychiatry and Clinical Neurosciences, Vol. 62, no.2, p. 203-213 (2008)
Permanent URL http://hdl.handle.net/2078/170198